WO2000021554A1 - Prevention et traitement de la cachexie - Google Patents
Prevention et traitement de la cachexie Download PDFInfo
- Publication number
- WO2000021554A1 WO2000021554A1 PCT/JP1999/005570 JP9905570W WO0021554A1 WO 2000021554 A1 WO2000021554 A1 WO 2000021554A1 JP 9905570 W JP9905570 W JP 9905570W WO 0021554 A1 WO0021554 A1 WO 0021554A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cachexia
- amino acid
- ocif
- active ingredient
- seq
- Prior art date
Links
- 206010006895 Cachexia Diseases 0.000 title claims abstract description 18
- 230000003449 preventive effect Effects 0.000 title abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 210000002997 osteoclast Anatomy 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 102000008108 Osteoprotegerin Human genes 0.000 abstract description 3
- 108010035042 Osteoprotegerin Proteins 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003269 anti-cachectic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- -1 infusion Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to an agent for preventing or treating cachexia comprising an osteoclast formation inhibitory factor (Ost. Eoclastogenesis Inhibitory Factor; hereinafter, referred to as FOCI Fj) as an active ingredient.
- an osteoclast formation inhibitory factor Ost. Eoclastogenesis Inhibitory Factor; hereinafter, referred to as FOCI Fj
- Fluid mainly causes progressive weight loss, anemia, edema, anorexia, etc., which develop in chronic diseases such as malignant tumors, tuberculosis, diabetes, blood diseases, endocrine diseases, infectious diseases and acquired immunodeficiency syndrome. It is a systemic disease that causes symptoms (see J. Parenteral and Enteral Nutrition. Vol. 12, 286-298, (1988): American Journal of Medicine, vol. 85, 289-291. (1988) ).
- OC.1 F is composed of the amino acid sequences described in Amino Acid Numbers 1 to 380 of SEQ ID NO: 1 and has been found as a protein having an activity of inhibiting osteoclast differentiation or maturation. And bone loss such as osteoporosis, osteoarthritis, multiple myeloma, etc. It is known to be useful as a preventive or therapeutic agent for bone metabolism and dysfunction (WO% / 262 ⁇ 7), however, the protein has a preventive and therapeutic effect on cachexia That isn't true. ' ⁇ ;
- OCIF or a mutant thereof exerts an excellent preventive or therapeutic effect on cachexia, and completed the present invention.
- a cachexia comprising, as an active ingredient, an osteoclast formation inhibitory factor (OCIF) comprising an amino acid sequence represented by any one of amino acid numbers 1 to 380 of SEQ ID NO: 1 or a mutant thereof.
- OCIF osteoclast formation inhibitory factor
- a preventive or therapeutic agent for cachexia comprising, as an active ingredient, an osteoclast formation inhibitory factor (OCIF) comprising an amino acid sequence represented by amino acid numbers 1 to 380 of SEQ ID NO: 1 in the sequence listing,
- OCIF osteoclast formation inhibitory factor
- mutant refers to a protein in which one or more amino acids in the amino acid sequence of OCIF have been substituted, deleted, added or inserted, and the OCIF activity (inhibition of osteoclast formation) is determined. Activity).
- the OC1 F protein can be produced by the method described in W096 / 26217 ...
- eukaryotic genes are considered to exhibit polymorphism as is known for interferon genes (eg, Nishi, T. et al. (1985) Biochem. HI, 153- 159), this polymorphism may result in the replacement of one or more amino acids, or the nucleotide sequence may be replaced but the amino acids remain the same.
- OCIF protein consisting of the amino acid sequences of amino acids 1 to 380 of SEQ ID NO: 1, one or more amino acid residues are substituted or deleted. Lost, added or inserted proteins often also have OCIF activity. In the present invention, these proteins are referred to as OCIF mutants. That is, as long as these naturally occurring or artificially synthesized proteins have OCIF activity, all of those proteins can be used in the present invention.
- DNA encoding such a protein can be obtained, for example, by the phosphite 'triester method (Nature, ⁇ , 105-111, (1984)! [!
- the codon for amino acid can be selected arbitrarily, for example, considering the codon usage of ⁇ : 3 ⁇ 4 ⁇ : to be used. (Refer to Nucleic Acid Res. I>, 143-174. (1981).) Further, partial modification of these nucleotide sequence codons can be carried out according to a conventional method. Site-directed mutagenesis / Proc. Natl. Acad. Sci. USA 81, 5662-5666, (] 984) using the primer consisting of the synthetic nucleotide to be used.
- any -- ⁇ 'or multiple amino acid residues may be deleted.
- the DNA is trimmed from the end using exonuclease Bal3l (see “Seismological Chemistry Laboratory Lecture 1, Genetic Research Method II”, pages 335-354), cassette mutation (Refer to “Shinogen Chemistry Laboratory Course 2: Nucleic Acid I] I Recombinant DNA Technology”, pp. 242-251.)
- the codon for the amino acid is known per se, and Selection is optional, and can be determined according to a conventional method, taking into account, for example, the codon usage of the ffj host.
- the OC [F activity can be measured by the method described in W096 / 26217.
- the term "cachexia” refers to a progressive weight loss, anemia, which develops in chronic diseases such as malignant tumors, tuberculosis, diabetes, blood diseases, endocrine diseases, infectious diseases and acquired immunodeficiency syndrome. It refers to a systemic disease with edema and anorexia as the main symptoms.
- OCIF protein represented by amino acid No. 1-No. 3H0 of SEQ ID NO: 1
- OCIF was 0.0% Tween80 in PBS.
- Body change ( ⁇ ) body weight on day 12 after cancer transplantation (g) Body weight on day 7 after cancer transplantation
- Body ® "yl birefringence index (%) Double ( ⁇ Alpha - delta beta) / ( ⁇ c - ⁇ ⁇ ) X 1 0 0
- Example 1 According to the method described in the above, mouse colon cancer Colon26 cells of about 2 mm square were transplanted under the skin of 10 Balb / c mice (female, 7 weeks old) per group.
- Life extension activity was evaluated by the survival rate (%) according to the following formula. Life extension (%) ' ⁇ (A /-1) X 1 0 0
- the cachexia preventive or therapeutic agent containing OC1F of the present invention or a variant thereof as an active ingredient is a water-soluble sterile solution or suspension of adipule dissolved in another pharmacologically acceptable solution. It is also used as a sterile powder formulation (filled in an ampoule with J, preferably a solution of OCIF or a variant thereof, which is preferably dried and dried), and simultaneously diluted with a pharmacologically acceptable solution.
- the prophylactic or therapeutic agent for serum of the present invention contains OCIF or a mutant thereof as an active ingredient, and can be administered in various forms.
- the administration form include oral administration by tablets, capsules, granules, powders, and syrups, and parenteral administration by injection, infusion, suppository and the like.
- the dosage varies depending on symptoms, age, body weight, etc., but in general, for oral administration, it is about 0.1 mg to 1000 mg per day for an adult, and these may be divided into one or several doses. Can be administered. In addition, for parenteral administration, 0.1 mg or 1000 mg can be administered by subcutaneous injection, intramuscular injection or intravenous injection once.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cette invention concerne des substances utilisées pour la prévention ou le traitement de la cachexie qui renferment comme principe actif un facteur inhibiteur de l'ostéoclastogenèse ou une variante de ce facteur.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60060/99A AU6006099A (en) | 1998-10-09 | 1999-10-08 | Preventives or remedies for cachexia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/287738 | 1998-10-09 | ||
JP28773898 | 1998-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000021554A1 true WO2000021554A1 (fr) | 2000-04-20 |
Family
ID=17721126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/005570 WO2000021554A1 (fr) | 1998-10-09 | 1999-10-08 | Prevention et traitement de la cachexie |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6006099A (fr) |
WO (1) | WO2000021554A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002097033A2 (fr) | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Anticorps se liant de maniere immunospecifique a des recepteurs de trail |
US7749960B2 (en) | 2001-04-03 | 2010-07-06 | Nestec S.A. | Osteoprotegerin in milk |
US8703725B2 (en) | 2002-09-20 | 2014-04-22 | Nestec S.A. | Nutritional compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0816380A1 (fr) * | 1995-02-20 | 1998-01-07 | Snow Brand Milk Products Co., Ltd. | Proteine nouvelle et ses procedes de production |
WO1998012344A1 (fr) * | 1996-09-18 | 1998-03-26 | Human Genome Sciences, Inc. | Genes de type recepteurs du facteur de necrose tumorale humain |
-
1999
- 1999-10-08 AU AU60060/99A patent/AU6006099A/en not_active Abandoned
- 1999-10-08 WO PCT/JP1999/005570 patent/WO2000021554A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0816380A1 (fr) * | 1995-02-20 | 1998-01-07 | Snow Brand Milk Products Co., Ltd. | Proteine nouvelle et ses procedes de production |
WO1998012344A1 (fr) * | 1996-09-18 | 1998-03-26 | Human Genome Sciences, Inc. | Genes de type recepteurs du facteur de necrose tumorale humain |
Non-Patent Citations (1)
Title |
---|
YASUDA H. ET AL.: "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis", ENDOCRINOLOGY, vol. 139, no. 3, March 1998 (1998-03-01), pages 1329 - 1337 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7749960B2 (en) | 2001-04-03 | 2010-07-06 | Nestec S.A. | Osteoprotegerin in milk |
WO2002097033A2 (fr) | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Anticorps se liant de maniere immunospecifique a des recepteurs de trail |
US8703725B2 (en) | 2002-09-20 | 2014-04-22 | Nestec S.A. | Nutritional compositions |
Also Published As
Publication number | Publication date |
---|---|
AU6006099A (en) | 2000-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108026533B (zh) | 拮抗性pdl1适体及其在癌症治疗中的应用 | |
JP5709354B2 (ja) | mTOR阻害剤投与によるがん患者の治療 | |
JP5357857B2 (ja) | 抗ガン剤及びdna複製阻害剤 | |
JP2013543879A (ja) | 急性骨髄性白血病を治療するための単独またはシタラビンとの組合せにおけるボラセルチブ | |
KR20040018341A (ko) | 암치료용 약제 조성물 | |
WO1996035430A1 (fr) | TRAITEMENT ET PREVENTION DE MALADIES ASSOCIEES A NF-λB | |
EP1809660B1 (fr) | Proteine specifique au thymus | |
IL272166B2 (en) | A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(s3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-h7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment | |
JP2009138005A (ja) | ルテニウム(iii)錯体および複素環を含む組成物 | |
EP1894575B1 (fr) | Agent thérapeutique contre le cancer | |
TW201122103A (en) | Tnf antagonists and tnf inhibitors comprising the same as the active ingredient | |
EP0758549A1 (fr) | Composition medicinale servant de medicament contre le cancer bronchopulmonaire "non a petites cellules" | |
CN111297866A (zh) | 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途 | |
WO2000021554A1 (fr) | Prevention et traitement de la cachexie | |
EP1208840B1 (fr) | Composition pour le traitement des métastases ou du cancer contenant du fluorouracil et un agent de transfert de métylol | |
US20090286861A1 (en) | Phenotypic reversion of pancreatic carcinoma cells | |
EP2117539B1 (fr) | Procédé d'administration d'un composé anti-tumeur | |
JP2002509532A (ja) | アルグラビン(arglabin)およびアルグラビン誘導体の薬学的組成物 | |
CN115243719A (zh) | CTB006与Ponatinib联合应用 | |
JP2000178200A (ja) | 悪液質予防剤、又は治療剤 | |
US20220387475A1 (en) | Methods and compositions for treating endometriosis | |
EP4331614A1 (fr) | Utilisation d'un médicament dans le traitement d'une maladie tumorale | |
JP4395901B2 (ja) | 新規遺伝子治療用薬剤 | |
US11298366B2 (en) | Ibandronate conjugates of nucleoside antimetabolites | |
US6331528B1 (en) | Method for treatment in gene therapy and use of guanine derivative therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU ID IL IN KR MX NO NZ PL RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase |